Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Manzamine A is a marine-derived, β-carboline-fused pentacyclic alkaloid found in several marine sponge genera, including Haliclona and Acanthostrongylophora. It demonstrates diverse biological activities, including anticancer, antimalarial, antiviral (notably against HSV-1 and HIV-1), anti-hyperlipidemic, anti-atherosclerotic, antimicrobial, and potential neuroprotective effects. Mechanistically, Manzamine A is known to inhibit Glycogen Synthase Kinase-3 (GSK-3), modulate SIX1 gene expression, disrupt autophagy by uncoupling vacuolar ATPases, and inhibit other proteins involved in cellular proliferation (e.g., JAK2, AKT, PKC, FAK, Bcl-2, IκB). It causes cell cycle arrest, suppresses the epithelial–mesenchymal transition, and can induce apoptosis in various cancer cell types. It is being actively investigated in preclinical and early-phase research for multiple therapeutic areas including cancer, Alzheimer’s disease, and infectious diseases[1][2][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on manzamine a.